| Successful treatment of refractory donor lymphocyte infusion-induced immune-mediated pancytopenia with rituximab. | |
| | |
MedLine Citation:
|
PMID: 19890900 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A 6-year-old male with chronic granulomatous disease, who was transplanted with bone marrow and exhibited increasing mixed chimerism, subsequently received two donor lymphocyte infusions (DLI). Two weeks after the second DLI, the patient developed acute graft-versus-host disease (GVHD) and progressive pancytopenia that was associated with autoantibody production. Conventional treatment did not improve the pancytopenia. However, administration of Rituximab (RTX) (375 mg/m(2)/week for four consecutive weeks) resulted in a rapid resolution of the pancytopenia. The patient achieved full donor chimerism without GVHD symptoms. RTX can be valuable for managing immune-mediated cytopenias that arise after DLI and are refractory to conventional therapies. |
| | |
Authors:
|
Itaru Kato; Katsutsugu Umeda; Tomonari Awaya; Yoshihiro Yui; Akira Niwa; Hisanori Fujino; Hiroshi Matsubara; Ken-Ichiro Watanabe; Toshio Heike; Naoto Adachi; Fumio Endo; Tomoyuki Mizukami; Hiroyuki Nunoi; Tatsutoshi Nakahata; Souichi Adachi |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Pediatric blood & cancer Volume: 54 ISSN: 1545-5017 ISO Abbreviation: Pediatr Blood Cancer Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2009-12-17 Completed Date: 2010-01-26 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101186624 Medline TA: Pediatr Blood Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 329-31 Citation Subset: IM |
Copyright Information:
|
(c) 2009 Wiley-Liss, Inc. |
Affiliation:
|
Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
therapeutic use* Bone Marrow Transplantation Graft vs Host Disease / drug therapy*, etiology Granulomatous Disease, Chronic / therapy Humans Immunologic Factors / therapeutic use* Infant Lymphocyte Transfusion / adverse effects* Male Pancytopenia / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunologic Factors; 0/rituximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Noninvasive Imaging Surrogate of Angiogenesis in Osteosarcoma.
Next Document: FDG PET imaging of childhood sarcomas.